Gabapentinoid dosing and adverse events in patients with chronic kidney disease
Clinical Nephrology · 01.09.2022 · 98 (3) · 147-154
DOI: 10.5414/cn110815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.09.2022. Verfasst von Drew A Wells und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antipsychotic Agents, Kidney Failure, Chronic, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Wells, D. A., Washington, K., Cave, B., Zhu, R., & Hudson, J. Q. (2022). Gabapentinoid dosing and adverse events in patients with chronic kidney disease. Clinical Nephrology, 98(3), 147-154. https://doi.org/10.5414/cn110815
Vancouver
Wells DA, Washington K, Cave B, Zhu R, Hudson JQ. Gabapentinoid dosing and adverse events in patients with chronic kidney disease. Clinical Nephrology. 2022;98(3):147-154. doi:10.5414/cn110815
BibTeX
@article{Wells2022,
author = {Wells, Drew A and Washington, Kayla and Cave, Brandon and Zhu, Rongshun and Hudson, Joanna Q},
title = {Gabapentinoid dosing and adverse events in patients with chronic kidney disease},
journal = {Clinical Nephrology},
year = {2022},
volume = {98},
number = {3},
pages = {147--154},
doi = {10.5414/cn110815}
}
EUVIMED